EP0180398A1
(en)
|
1984-10-26 |
1986-05-07 |
The Regents Of The University Of California |
Synthesis of beta-lactam
|
CA1305177C
(en)
|
1987-06-30 |
1992-07-14 |
Yasufumi Ohfune |
Carboxycyclopropylglycine and process for producing the same
|
US4904681A
(en)
|
1987-12-01 |
1990-02-27 |
G. D. Searle & Co. |
D-cycloserine and its prodrugs as cognitive enhancers
|
EP0360390A1
(en)
|
1988-07-25 |
1990-03-28 |
Glaxo Group Limited |
Spirolactam derivatives
|
US5061721A
(en)
|
1989-03-15 |
1991-10-29 |
G. D. Searle & Co. |
Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
WO1992007561A1
(fr)
|
1990-10-30 |
1992-05-14 |
Ss Pharmaceutical Co., Ltd. |
Preparation d'un gel anti-inflammatoire et analgesique
|
US5168103A
(en)
|
1991-01-22 |
1992-12-01 |
American Home Products Corporation |
[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
|
FR2692268B1
(fr)
|
1992-06-15 |
1994-08-19 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
|
SE9301667D0
(sv)
|
1993-05-14 |
1993-05-14 |
Kabi Pharmacia Ab |
New use
|
US5523323A
(en)
|
1993-09-14 |
1996-06-04 |
Maccecchini; Maria-Luisa |
Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
|
US5605911A
(en)
|
1995-01-31 |
1997-02-25 |
Washington University |
Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
|
US6335358B1
(en)
|
1995-04-12 |
2002-01-01 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
US5763393A
(en)
|
1996-05-17 |
1998-06-09 |
Neurotherapeutics L.P. |
Neuroactive peptides
|
WO1997046578A1
(en)
|
1996-06-07 |
1997-12-11 |
Zeneca Limited |
Peptide derivatives
|
AU3972797A
(en)
|
1996-08-02 |
1998-02-25 |
Zymogenetics Inc. |
Testis-specific insulin homolog polypeptides
|
US5902815A
(en)
|
1996-09-03 |
1999-05-11 |
Washington University |
Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
|
JP3955345B2
(ja)
|
1996-09-27 |
2007-08-08 |
サントリー株式会社 |
新規アミノ酸ダイジハーベイン
|
WO1999024584A1
(en)
|
1997-11-12 |
1999-05-20 |
Neurotherapeutics |
Methods for the detection and treatment of disease using a glycosyltransferase
|
US5952389A
(en)
|
1998-01-13 |
1999-09-14 |
Synchroneuron |
Methods of treating tardive dyskinesia and other movement disorders
|
US6007841A
(en)
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
US6274314B1
(en)
|
1998-04-02 |
2001-08-14 |
Nyxis Neurotherapies, Inc. |
Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
|
US6197820B1
(en)
|
1998-04-06 |
2001-03-06 |
Uab Research Foundation |
Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
|
US6025471A
(en)
|
1998-06-03 |
2000-02-15 |
Deghenghi; Romano |
Diazaspiro, azepino and azabicyclo therapeutic peptides
|
WO2000027790A1
(en)
|
1998-11-11 |
2000-05-18 |
Smithkline Beecham P.L.C. |
Mutilin compounds
|
AU1724000A
(en)
|
1998-11-12 |
2000-05-29 |
Nyxis, Inc. |
Diagnostic assay for cancer
|
US20030064921A1
(en)
|
1999-10-27 |
2003-04-03 |
The Regents Of The University Of California |
Methods and compounds for modulating melanocortin receptor ligand binding and activity
|
WO2001036685A2
(en)
|
1999-11-17 |
2001-05-25 |
Nyxis Neurotherapies, Inc. |
Differential gene expression in cancer
|
AU782678B2
(en)
|
2000-02-01 |
2005-08-18 |
Agy Therapeutics, Inc. |
Interaction of NMDA receptor with protein tyrosine phosphatase
|
JP2001261679A
(ja)
|
2000-03-21 |
2001-09-26 |
Mitsui Chemicals Inc |
ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
|
WO2001096606A2
(en)
|
2000-06-14 |
2001-12-20 |
Nyxis Neurotherapies, Inc. |
Identification of genes and compounds for treatment of cancer
|
WO2001098367A2
(en)
|
2000-06-22 |
2001-12-27 |
Nyxis Neurotherapies, Inc. |
Neuroactive peptides for treatment of hypoxia and related conditions
|
GB0018272D0
(en)
|
2000-07-25 |
2000-09-13 |
Vernalis Research Limited |
Chemical compounds IV
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
EP1186303A3
(en)
|
2000-09-06 |
2003-12-10 |
Pfizer Products Inc. |
Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
|
UA73619C2
(en)
|
2000-12-13 |
2005-08-15 |
Pfizer Prod Inc |
Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
|
US20020142287A1
(en)
|
2000-12-14 |
2002-10-03 |
Hirotaka Yamamoto |
High throughput assay to detect inhibitors of the map kinase pathway
|
US20030065138A1
(en)
|
2001-03-07 |
2003-04-03 |
University Of Utah Research Foundation |
Linear gamma-carboxyglutamate rich conotoxins
|
AU2002255705A1
(en)
|
2001-03-12 |
2002-09-24 |
Nyxis Neurotherapies, Inc |
Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
|
WO2003010540A1
(en)
|
2001-07-25 |
2003-02-06 |
Nyxis Neurotherapies, Inc. |
Method of identifying nmda-related agent
|
AU2003245753B2
(en)
|
2002-07-05 |
2009-12-24 |
Targacept, Inc. |
N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
WO2004094371A2
(en)
*
|
2003-04-17 |
2004-11-04 |
Merck & Co., Inc. |
Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
|
CA2573951A1
(en)
|
2003-07-18 |
2005-01-27 |
Virochem Pharma Inc. |
Spiro compounds and methods for the modulation of chemokine receptor activity
|
CA2534909A1
(en)
|
2003-08-08 |
2005-02-17 |
The Burnham Institute |
P16 mediated regulation of nmda receptors
|
WO2005020973A2
(en)
|
2003-08-29 |
2005-03-10 |
The University Of Houston System |
Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
|
GB0323204D0
(en)
|
2003-10-03 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
US20070275990A1
(en)
|
2003-11-13 |
2007-11-29 |
Ono Pharmaceutical Co., Ltd. |
Heterocyclic Spiro Compound
|
CA2552914C
(en)
|
2004-01-08 |
2010-09-14 |
F.Hoffmann-La Roche Ag |
Diaza-spiropiperidine derivatives
|
US20060063707A1
(en)
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
CN101090902B
(zh)
|
2004-10-13 |
2013-05-29 |
默沙东公司 |
Cgrp受体拮抗剂
|
ATE520404T1
(de)
|
2005-03-24 |
2011-09-15 |
Univ Emory |
Verfahren zur behandlung einer verletzung des zentralen nervensystems durch ausschleichende verabreichung von progesteron
|
US7951912B2
(en)
|
2005-08-26 |
2011-05-31 |
Wisconsin Alumni Research Foundation |
Poly-β-peptides from functionalized β-lactam monomers and antibacterial compositions containing same
|
AR059224A1
(es)
|
2006-01-31 |
2008-03-19 |
Jerini Ag |
Compuestos para la inhibicion de integrinas y uso de estas
|
US20070208001A1
(en)
|
2006-03-03 |
2007-09-06 |
Jincong Zhuo |
Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
|
MX2009002921A
(es)
|
2006-09-15 |
2009-04-01 |
Schering Corp |
Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
|
JP2008188285A
(ja)
|
2007-02-06 |
2008-08-21 |
Bridgestone Corp |
バックパッド及び車両用シート
|
CA2682195A1
(en)
|
2007-03-20 |
2008-09-25 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
CN101066945B
(zh)
|
2007-05-25 |
2010-05-19 |
中国科学院上海有机化学研究所 |
一种合成3-位取代内酰胺类化合物的方法
|
CN101125817B
(zh)
|
2007-08-03 |
2011-09-14 |
中国科学院上海有机化学研究所 |
一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
|
US20090054392A1
(en)
|
2007-08-20 |
2009-02-26 |
Wyeth |
Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
|
WO2009039390A2
(en)
|
2007-09-20 |
2009-03-26 |
Naurex Inc. |
The development of glycobiology-based therapeutics for the treatment of brain tumors
|
AU2009217278B2
(en)
|
2008-02-20 |
2015-08-20 |
The Children's Hospital Of Philadelphia |
Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
|
MX2010013946A
(es)
|
2008-06-24 |
2011-02-15 |
Intervet Int Bv |
Composiciones transdermicas farmaceuticas y metodo para tratar la inflamacion en ganado.
|
KR20110025226A
(ko)
|
2008-06-27 |
2011-03-09 |
뉴로서치 에이/에스 |
신규한 테트라메틸 치환된 피페리딘 유도체 및 모노아민 신경전달물질 재흡수 억제제로서의 이의 용도
|
KR101647520B1
(ko)
|
2008-08-07 |
2016-08-10 |
에프. 호프만-라 로슈 아게 |
거대환식 화합물의 제조 방법
|
GB0814991D0
(en)
|
2008-08-15 |
2008-09-24 |
Glaxo Group Ltd |
Compounds
|
JP5702288B2
(ja)
|
2008-09-18 |
2015-04-15 |
ノースウエスタン ユニバーシティ |
Nmdaレセプターモジュレータ及びその用途
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
DE102009001460B4
(de)
|
2009-03-11 |
2010-12-02 |
Zf Friedrichshafen Ag |
Ölbehälter
|
US8329904B2
(en)
|
2009-05-12 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
US20120178695A1
(en)
|
2009-07-02 |
2012-07-12 |
Joseph Moskal |
Methods of treating neuropathic pain
|
PT2485751E
(pt)
|
2009-10-05 |
2014-09-01 |
Univ Northwestern |
Glyx-13 para uso num método para tratar depressão refratária
|
US8951968B2
(en)
|
2009-10-05 |
2015-02-10 |
Northwestern University |
Methods of treating depression and other related diseases
|
US8871208B2
(en)
|
2009-12-04 |
2014-10-28 |
Abbvie Inc. |
11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
|
AR079553A1
(es)
*
|
2009-12-21 |
2012-02-01 |
Novartis Ag |
Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros.
|
WO2011100585A1
(en)
|
2010-02-11 |
2011-08-18 |
Joseph Moskal |
Secondary structure stabilized nmda receptor modulators and uses thereof
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
2차 구조 안정화된 nmda 수용체 조절제 및 그의 용도
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
US8097634B2
(en)
|
2010-04-15 |
2012-01-17 |
Hoffmann-La Roche Inc. |
Azacyclic derivatives
|
GB201007789D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel Compound
|
GB201007791D0
(en)
|
2010-05-10 |
2010-06-23 |
Glaxo Group Ltd |
Novel compounds
|
CN102267995A
(zh)
|
2010-06-04 |
2011-12-07 |
艾琪康医药科技(上海)有限公司 |
一种制备二氮杂螺环化合物的方法
|
WO2012021712A1
(en)
|
2010-08-12 |
2012-02-16 |
Tetraphase Pharmaceuticals, Inc. |
Tetracycline analogs
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
PE20140976A1
(es)
|
2011-03-14 |
2014-08-28 |
Boehringer Ingelheim Int |
Inhibidores de benzodioxano de la producion de leucotrieno
|
SG194230A1
(en)
|
2011-04-27 |
2013-12-30 |
Univ Northwestern |
Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
|
JP6388536B2
(ja)
|
2011-06-27 |
2018-09-12 |
コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. |
超音波振動子アセンブリ及びその製造方法
|
CN105254616B
(zh)
|
2011-07-27 |
2017-10-17 |
阿斯利康(瑞典)有限公司 |
取代的n‑(2‑甲氧基‑5‑硝基苯基)嘧啶‑2‑胺化合物及其盐
|
AR092031A1
(es)
|
2012-07-26 |
2015-03-18 |
Merck Sharp & Dohme |
Inhibidores del canal de potasio medular externo renal
|
BR112015018094A2
(pt)
|
2013-01-29 |
2017-07-18 |
Naurex Inc |
moduladores de receptor nmda de espiro-lactama e usos dos mesmos
|
PE20151427A1
(es)
*
|
2013-01-29 |
2015-10-10 |
Naurex Inc |
Moduladores de receptores nmda de espiro-lactama y sus usos
|
CA2898861C
(en)
|
2013-01-29 |
2021-07-20 |
Naurex, Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
MX2015009778A
(es)
|
2013-01-29 |
2016-02-09 |
Aptinyx Inc |
Moduladores de receptores nmda de espiro-lactama y sus usos.
|
CN105229010A
(zh)
|
2013-01-29 |
2016-01-06 |
阿普廷伊克斯股份有限公司 |
螺-内酰胺nmda受体调节剂及其用途
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
GB201416346D0
(en)
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
WO2017201285A1
(en)
|
2016-05-19 |
2017-11-23 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
MX2018014202A
(es)
|
2016-05-19 |
2019-06-20 |
Aptinyx Inc |
Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
|
MX2019001319A
(es)
|
2016-08-01 |
2019-07-04 |
Aptinyx Inc |
Moduladores del receptor nmda espiro-lactam y uso de los mismos.
|
CA3031562A1
(en)
|
2016-08-01 |
2018-02-08 |
Aptinyx Inc. |
Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
|
JP7036792B2
(ja)
|
2016-08-01 |
2022-03-15 |
アプティニックス インコーポレイテッド |
スピロ-ラクタムnmda受容体修飾因子およびその使用
|
JP7032378B2
(ja)
|
2016-08-01 |
2022-03-08 |
アプティニックス インコーポレイテッド |
スピロ-ラクタムnmda受容体修飾因子及びその使用
|
KR102538803B1
(ko)
|
2016-08-01 |
2023-06-01 |
앱티닉스 인크. |
스피로-락탐 nmda 조정제 및 그의 사용 방법
|
AU2019215058A1
(en)
|
2018-01-31 |
2020-09-17 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
US20210047324A1
(en)
|
2018-01-31 |
2021-02-18 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
US20210139489A1
(en)
|
2019-11-11 |
2021-05-13 |
Aptinyx Inc. |
Methods of treating painful diabetic peripheral neuropathy
|
US20210308101A1
(en)
|
2019-11-11 |
2021-10-07 |
Aptinyx Inc. |
Methods of treating fibromyalgia
|
AU2020398840A1
(en)
|
2019-12-04 |
2022-05-26 |
Aptinyx Inc. |
Methods of treating cognitive impairment associated with neurodegenerative disease
|